亿帆医药(002019.SZ)：在研产品断金戒毒胶囊Ib期临床试验结果达到预期目标

Core Viewpoint - Yifan Pharmaceutical's subsidiary has successfully completed Phase Ib clinical trials for the "Duanjin Detoxification Capsule," demonstrating its safety, tolerability, and pharmacokinetic characteristics in treating opioid addiction relapse prevention [1][2]. Group 1: Clinical Trial Results - The Duanjin Detoxification Capsule has shown a significant trend in preventing relapse, improving behavioral control, and enhancing recovery quality compared to a placebo in patients recovering from opioid addiction [1]. - The clinical trials included three studies conducted domestically, with a total of 114 healthy adult participants involved in various dosing studies [2]. Group 2: Product Composition and Function - The Duanjin Detoxification Capsule is a traditional Chinese medicine capsule developed based on folk experience, primarily composed of "Gouwen" and "Yangjinhua," aimed at alleviating opioid addiction symptoms [1]. - The capsule is indicated for symptoms such as drug craving, anxiety, sleep disturbances, fatigue, and appetite loss [1]. Group 3: Research and Development Investment - The company has invested approximately RMB 98.283 million in the research and development of the Duanjin Detoxification Capsule to date [3].